Chelsea and Westminster Hospital has launched all-operator mobile connectivity after deploiying a new distributed antenna system (DAS).
Clinical Study of Non-invasive 40-Hz Audiovisual Stimulation Guided by Gamma EEG Monitoring for Promoting Perioperative Brain Function Recovery in Children
Conditions: ADHD – Attention Deficit Disorder With Hyperactivity
Interventions: Device: 40-Hz non-invasive synchronized audiovisual stimulation
Sponsors: General Hospital of Ningxia Medical University
Not yet recruiting
Interventions: Device: 40-Hz non-invasive synchronized audiovisual stimulation
Sponsors: General Hospital of Ningxia Medical University
Not yet recruiting
Diagnostic Discrimination of BOKE STARS, a Bimodal Continuous Performance Test, for Attention-Deficit/Hyperactivity Disorder Assessment in Chinese Children: Single-Center Case-Control Study
Background: Attention-deficit/hyperactivity disorder (ADHD) affects 6.3% of Chinese children, but only 10% are diagnosed, as diagnosis is hindered by low awareness and lack of culturally adapted, objective tools. Existing continuous performance tests are unimodal and lack validity. Objective: This study aimed to conduct an initial evaluation of the diagnostic discrimination of BOKE STARS (Sustained Task and Attention Response Screening), a culturally adapted bimodal continuous performance test, for distinguishing children with ADHD from typically developing children in a Chinese clinical setting. Methods: In this prospective, single-center diagnostic accuracy study with a case-control design, 100 children aged 6 to 12 years (n=50 with ADHD and n=50 controls) were recruited at Xinhua Hospital between January and May 2024. Parents completed the Swanson, Nolan, and Pelham Rating Scale–fourth version (SNAP-IV), and children completed the BOKE STARS assessment on a tablet device under standardized conditions. Group comparisons were conducted using independent-sample 2-tailed tests or Mann-Whitney tests, as appropriate. Receiver operating characteristic (ROC) curve analysis was performed in the full case-control sample to assess diagnostic discrimination. Sensitivity and specificity were reported descriptively across ROC-derived cutoffs; these cutoffs were not interpreted as clinically validated diagnostic thresholds. Secondary exploratory analyses included comparisons among ADHD subtypes and correlations between BOKE STARS indices and parent-reported SNAP-IV symptom severity scores. Results: Compared with controls, children with ADHD performed significantly worse on all major BOKE STARS indices, including errors of omission, errors of commission, reaction time, reaction time variability (RTV), discrimination prime, and total score. In the full case-control sample, the total score showed the strongest diagnostic discrimination (area under the ROC curve [AUC] 0.962, 95% CI 0.931-0.992), followed by RTV (AUC 0.919, 95% CI 0.867-0.971), errors of omission (AUC 0.884, 95% CI 0.818-0.950), and discrimination prime (AUC 0.819, 95% CI 0.737-0.900). Errors of commission (AUC 0.689, 95% CI 0.585-0.792) and reaction time (AUC 0.634, 95% CI 0.524-0.743) showed comparatively weaker discrimination. No significant differences were observed among ADHD subtypes. Several BOKE STARS indices were modestly correlated with SNAP-IV inattention and hyperactivity or impulsivity scores. Conclusions: BOKE STARS showed promising preliminary diagnostic discrimination for identifying Chinese children with ADHD in this case-control sample, with the total score and RTV showing the strongest discriminatory performance. However, because the case-control design artificially fixed the ratio of ADHD cases to controls, diagnostic performance estimates and exploratory cutoffs should be interpreted cautiously and should not be considered representative of real-world clinical diagnostic performance. BOKE STARS may serve as an adjunctive assessment tool to complement clinical interviews and caregiver-reported rating scales, but further external validation in larger and clinically heterogeneous populations is required before broader clinical implementation.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/a352c65e649b80c4b66c3ed01598115e" />
10x Clinical Expansion Advances with CLIA Lab Plans, Cleveland Clinic Partnership
10x Genomics says it is on track to build out a CLIA-certified laboratory set to open next year, part of the spatial and single-cell tools developer’s expansion into clinical diagnostics launched earlier this year.
The lab will open within 10x’s headquarters campus in Pleasanton, CA, 10x co-founder and CEO Serge Saxonov, PhD, told GEN.
“This is one great benefit that we have from the fact that we’ve got all the infrastructure here, and that’s why we feel like we can really accelerate some of these kinds of applications: Because we have the space, we have the expertise with the technology, we have the people who really know all the ins and outs of it, and we can very quickly, validate, new assays, test them, refine them, optimize them,” Saxonov said. “We have been seeing that already, in the time that we have been standing up some of these pieces, how enabling it is to have it all under one roof at this stage.
“Building a CLIA lab is definitely not a trivial undertaking, but we’ve been making really great progress,” he added. “The team has been standing up these capabilities, and definitely on track for early next year. So, very much looking forward to that.”
The CLIA lab is a key component of 10x’s move into clinical diagnostics, announced in January. Traditionally focused on research tools for academic, government, and industry customers, 10x has moved this year to launch clinical collaborations with top-tier institutions—the most recent of which was announced last month with Cleveland Clinic.
The nonprofit multispecialty academic medical center is partnering with 10x in a multi-year collaboration aimed at advancing research in novel diagnostics for bladder cancer. Cleveland Clinic has agreed to contribute patient samples with appropriate phenotypes for analysis on 10x’s Flex Apex single cell sequencing and Xenium spatial biology platforms.
“They have great access to patients and the right kinds of clinical trials and therapies that are going through their system,” Saxonov said. “We are working together to run single-cell and spatial analyses on them, collaborating on those and correlating the biology that we learn from single cell and spatial with therapeutic outcomes.”
Bladder cancer biomarkers
10x and Cleveland Clinic aim to identify biomarkers that predict how bladder cancer patients will respond to emerging therapies, such as immunotherapies and antibody-drug conjugates (ADCs).
“Those biomarkers are definitionally known already, but the actual context of their expression isn’t really that well known in terms of being able to predict response,” Saxonov explained. “The question is, if you see their expression in the context of the cancer cells, or the tumor microenvironment, or the immune compartment, it will then also inform response to therapy. And there’s plenty of evidence from scientific literature that there’s a lot of signal there, a really, really powerful signal there. What hasn’t been done is run rigorous, well-powered, clinically, really carefully well-defined studies to measure and evaluate those kinds of biomarkers.”
Oncology is one of two therapeutic areas viewed as priorities for pursuing translational applications with an eye toward potential clinical diagnostics that address therapy selection and monitoring. The other area is autoimmune disease.
Saxonov asserted that 10x’s clinical push was unrelated to its established research business, which shrank last year as its traditional base of academic and government (A&G) customers reeled from cuts in research funding. The cut prompted 10x to announce plans to eliminate about 100 jobs—8% of its workforce—though the workforce appears to have only shrunk by 18 jobs or about 4% last year, from 491 full-time employees as of December 31, 2024, to 473 at the end of last year, according to the company’s form 10-K annual filings.
“We feel our research business gives us an awesome foundation to now invest in this future of clinical applications. It is a very, very much an enabling thing,” Saxonov said. “It gives us a great foundation from which to go forward. It was always our plan, always our mission, always the strategy of the company that over time, as we develop our technologies, we want most naturally to make them actually have a direct clinical impact.”
Several recent trends have combined to support clinical expansion, Saxonov said:
- An increasing number of therapies whose effectiveness in patients, and in what combination, remains unknown to many doctors.
- A growing body of single-cell spatial signals, such as gene and protein expression, mapped to the exact physical coordinates of individual cells within a tissue.
- Increased maturing of single cell, spatial, and multiomics technologies, resulting in more data and higher quality insights that enable their use in the clinic.
‘A really nice position’
“Investments around workflow, investments around logistics, being able to work with distributed collected samples, and also being able to drive the costs down and scale up these technologies—all of that progress now puts us in a really nice position to lean into, first, generating clinical evidence for all these different, therapeutic areas, then taking the resulting information and deploying that in the context of diagnostic tests in the future,” Saxonov said.
“Independent of whatever might be happening in terms of the research market, which will fluctuate over time, is that several large-scale trends have been converging.”
Is 2026 shaping up as an up year or a down year for A&G? Saxonov said he’ll offer insights when 10x releases its second quarter earnings in August.
10x announced its clinical ambitions in January during the J.P. Morgan 44th Healthcare Conference in San Francisco. The company unveiled clinical collaborations with two Boston-based institutions, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, as well as the New York-based Cancer Research Institute.
The Cancer Research Institute collaboration focuses on generating “very large, AI-ready” data sets for immunotherapy, Saxonov said, while the Dana-Farber and Brigham and Women’s partnerships center more, like the Cleveland Clinic alliance, on generating clinical evidence for future diagnostics applications. Patient flows have been established, and analysis is underway in the collaborations with both Boston institutions.
“At the appropriate time, we’ll be updating the world about what we’re learning,” Saxonov added.
The post 10x Clinical Expansion Advances with CLIA Lab Plans, Cleveland Clinic Partnership appeared first on GEN – Genetic Engineering and Biotechnology News.
New Center for Therapeutic Genetics to Develop Rare Disease Genetic Medicines
It’s estimated that nearly 400 million people across the globe live with a rare disease. Though many of these diseases are progressive, debilitating, and even life-threatening, less than five percent of them have an effective and approved treatment.
Nearly half of the rare disease patients are children and it’s estimated that 30% of children with a rare disease will not survive past their fifth birthday. Though there have been some major successes in developing and providing treatment for some children with rare disease, including Baby KJ Muldoon—who was the first patient to receive a personalized CRISPR gene editing therapy—N = 1 therapies are challenging on many levels, and these stories cannot be the functional standard practice for treating patients with rare disease.
“What if treating genetic disease could be as routine as life-saving surgery?” ask David Liu, PhD, core institute member at the Broad Institute, and Winston Yan, MD, PhD, physician-scientist at the Broad institute and director of the new Center for Therapeutic Genetics (CTG) which is working to answer this very question.
“Scaling and sustaining treatment for ultra-rare disease is a hard problem that many scientists, clinicians, patients, and drug developers are working on,” says Yan.
Along with Yan and Lui, the CTG is founded by leaders in genetic medicine, including Cat Lutz, PhD, vice president, of The Jackson Laboratory’s rare disease translational center, Timothy Yu, MD, PhD, physician and researcher at Boston Children’s Hospital, and Wendy Chung, MD, PhD, chief of pediatrics at Boston Children’s Hospital. Their aim is simple: to develop genetic medicines that can treat patients with rare diseases in a scalable and repeatable way, while sharing the methods, data, and training learned through this practice.
“What we have here is a group of leaders who believe that by approaching genetic medicines not as products, but as a standardized clinical procedure, and by sharing what we learn openly across institutions, we can make precision genetic medicine faster, safer, less expensive, and more accessible to patients and families in need,” says Yan.
The impetus behind developing the CTG is centered on patient care and utilizing ever growing biotechnology.
“We receive messages every week from parents asking for help: Can we do for their child what has been done for other children who have received treatments?” shares Liu. “The honest answer today is usually ‘not yet,’ often not because the science doesn’t exist, but because we don’t yet have the infrastructure to bring these treatments to many patients. CTG is our commitment to closing that gap, so that eventually every family who needs this kind of treatment has a path forward.”
Though the center is in its founding phase and not yet working with patients, the programs are anticipated to include the development of precision gene-editing treatments for multiple diseases, including rare forms of genetic epilepsies, supported by a recent $34.5 million award from the ARPA-H THRIVE program.
“What we are building together is scalable treatment, something our institutions will learn to do well and repeat again and again. At Boston Children’s, we see children every day for whom a diagnosis is only the beginning of a much longer journey,” says Chung.
By utilizing technology, like CRISPR or base editing or prime editing, the goal is to develop a scalable system, not just one-off treatments. The founders of CTG aim to develop programmable and modular medicines that can be customized to the patient needs, not unlike the tailored pre-operational plans that are developed for each patient undergoing a standard practice surgery.
“We used to see precisely tailored therapies for children with genetic diseases as remarkable exceptions. CTG is built on the conviction that they don’t have to be—that the methods we develop for one rare disease will carry to the next, and eventually to the many,” says Yu.
Lutz concurs, adding, “We are at a moment in genomic medicine where, for many rare diseases, the question is no longer whether we can treat them, but whether we will build the systems to do it.”
Standardizing precision medical care using programmable genetic medicines for treating rare diseases is only the beginning. Best practices and processes for addressing rare disease can translate to treating more widespread diseases as well.
“CTG exists to close a major gap in care and ensure that what we learn from one disease accelerates treatment for the next,” concludes Chung.
The post New Center for Therapeutic Genetics to Develop Rare Disease Genetic Medicines appeared first on Inside Precision Medicine.
Illness perception, family resilience, and emotional distress among hospitalized older adults with multimorbidity in Xinjiang, China: a latent profile and mediation analysis
BackgroundOlder adults with multimorbidity frequently encounter significant psychological challenges, with negative illness perception being a prevalent issue. Such perceptions can intensify emotional distress. Family resilience—the ability of a family system to adapt positively to adversity—plays a crucial role in alleviating negative emotions, including anxiety and depression. This study aimed to investigate the heterogeneity of illness perception among older patients with multimorbidity and to assess the mediating effect of family resilience on the relationship between illness perception and emotional distress.Materials and MethodsBetween October 2025 and January 2026, 420 multimorbid older patients were recruited in three tertiary hospitals of Xinjiang Province. The evaluation was done based on the Brief Illness Perception Questionnaire, the Chinese version of the Family Resilience Assessment Scale, and the Hospital Anxiety and Depression Scale. The two methods of analysis were the latent profile analysis used to determine the unique patterns of illness perception and the bootstrap-based mediation analysis to determine whether family resilience mediates.ResultsThree distinct illness perception profiles were identified: low (32.6%), moderate (47.6%), and high (19.8%) illness perceptions. Using the low illness perception group as the reference, family resilience showed a significant partial mediating effect between moderate illness perception and anxiety (indirect effect = 0.510, 95% CI: 0.325–0.724), moderate illness perception and depression (indirect effect = 0.450, 95% CI: 0.283–0.631), high illness perception and anxiety (indirect effect = 1.263, 95% CI: 0.819–1.739), and high illness perception and depression (indirect effect = 1.114, 95% CI: 0.707–1.555).DiscussionThe results demonstrated heterogeneity in the perception of illness among older multimorbid patients, as a substantial percentage of the sample had moderate-to-high levels. Family resilience played a major partial mediating role between illness perception and emotional distress. The findings suggest the significance of shifting the clinical emphasis to the family system and integrating family resilience improvement as one of the psychological support measures for chronic patients.
Genomas Brasil program: building precision public health within Brazil’s Unified Health System
Nature Medicine, Published online: 21 July 2026; doi:10.1038/s41591-026-04523-2
Brazil is embedding large-scale genomics into its universal public healthcare system, combining sequencing, infrastructure and clinical implementation at scale. The experience may provide a model for other countries in the global south that seek to deliver genomic equity and precision public health.
Home Play-based Intervention for Parents and Infants
Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD); Autism Spectrum Disorder; Premature Birth; Global Developmental Delay
Interventions: Behavioral: SPRINT Intervention; Other: Waitlist Protocol
Sponsors: Nanyang Technological University; Agency for Science, Technology and Research (A*STAR); KK Women’s and Children’s Hospital; Institute for Human Development and Potential (IHDP), Singapore
Not yet recruiting
Interventions: Behavioral: SPRINT Intervention; Other: Waitlist Protocol
Sponsors: Nanyang Technological University; Agency for Science, Technology and Research (A*STAR); KK Women’s and Children’s Hospital; Institute for Human Development and Potential (IHDP), Singapore
Not yet recruiting
National digital pathology network expands to 15 NHS sites
The UK’s first national digital pathology platform has expanded, with 15 NHS sites now connected to the network.
Thyroid-stimulating hormone, fasting blood glucose and suicidal ideation in Chinese adolescents with major depressive disorder: a cross-sectional study
BackgroundThyroid function and glycolipid metabolic alterations are often associated with major depressive disorder (MDD), yet their roles in suicide risk among adolescents with MDD remain unclear. This study aimed to investigate thyroid-stimulating hormone (TSH) levels, glycolipid metabolism parameters, and their associations with suicidal ideation (SI) in adolescents with MDD.MethodsThis cross-sectional study was conducted at one general hospital and one psychiatric hospital in Anhui Province, China. Socio-demographic data and laboratory parameters were collected from participants, and the patients’ depressive symptoms and SI severity were assessed using the 24-item Hamilton Depression Rating Scale (HAMD-24) and the Positive and Negative Suicide Ideation Inventory (PANSI), respectively. TSH levels and glycolipid metabolism parameters were also measured.ResultsA total of 146 adolescents with MDD and 70 healthy controls (HCs) were enrolled in this study. Compared with HCs, patients had lower fasting blood glucose (FBG) levels (P < 0.001). Logistic regression analyses showed that a worse relationship with family, a higher HAMD-24 total score, and higher TSH and FBG levels were independently associated with concurrent SI in adolescents with MDD (all P < 0.05). Furthermore, receiver operating characteristic (ROC) curve analysis showed that the combination of these four factors had a good discriminatory ability for SI, with an area under the curve (AUC) of 0.851.ConclusionIn this cross-sectional study, TSH and FBG levels were associated with SI in adolescents with MDD. Nevertheless, whether these parameters can serve as clinically useful biomarkers requires further validation in larger prospective studies.